Condition
Malignant Pleural Mesothelioma
Estimated Enrollment: 12
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 1716-12
Study First Received: October 22, 2012
Last Updated: September 8, 2016
Estimated Primary Completion Date: March 2017
Primary Outcome Measures:
Safety and tolerability of HSV1716 given by single and repeat intrapleural administration in patients with inoperable malignant pleural mesothelioma.|Obtain evidence of HSV1716 replication and lysis of malignant pleural mesothelioma cells through analysis of pleural fluid and serum samples for evidence of cell death and/or HSV1716 replication and/or changes in appropriate biomarkers.
Sponsors and Collaborators:
Virttu Biologics Limited
Website Link: https://ClinicalTrials.gov/show/NCT01721018
